EGFR and esophageal adenocarcinoma: Since it is the first of its kind to report upon HER1 or HER3 overexpression in dysplastic Barrett’s esophagus, there is no standard clinically significant difference in the proportion of patient with overexpression of these RTKs upon which to base a power calculation.